products to reduce blood pressure must be taken from the market Heumann Pharma GmbH & Co. Genericar KG will be

medical devices recalls again of blood pressure reduction, because they were contaminated with harmful ingredients. According to the Federal Institute for drugs and medical devices (BfArM), the contamination is cancer-causing substances.

once again now so called blood pressure-lowering drugs are withdrawn from the market because they contain substances which can be carcinogenic, according to the Federal Institute for drugs and medical devices (BfArM). According to the manufacturer on its website is aware that there is an increased value of pollution with N-nitroso-N-methyl-4-aminobutyric acid (NMBA) in different batches with active ingredient Losartan. Even a simultaneous contamination by N-Nitrosodiethylamin (FERMILAB) and NMBA should have occurred in some production batches. A corresponding callback for the affected products was on the 07th March 2019 in the pharmaceutical paper, published Deutsche Apotheker Zeitung and corresponding media.

high blood pressure is widespread and threatens the health of those affected. Some drugs have been taken off the market now to lower blood pressure because they might contain carcinogenic substances. (Image:

these products are affected

the products are just in case withdrawn from the market, to prevent adverse health effects among users and users. Following batches are specifically affected by the recall. All batches of Losartan comp. Heumann 98, 28 and 56 film-coated tablets, 100 mg / 12.5 mg film-coated tablets, all lots beginning with the letters B and C by Losartan comp. Heumann 100 mg / 25 mg film-coated tablets, 98, 28 and 56 film-coated tablets.

medicines should be removed

customers without consultation, the drug should now but don’t settle without medical consultation which take advantage of the above mentioned products to lower their blood pressure, the manufacturer warns. The resulting health risk is higher than the potential risk posed by the existing pollution several times.

according to the manufacturer there is no acute patient risk. For further therapy, a doctor should be consulted as a result, the manufacturer adds on its homepage. (as)